Last reviewed · How we verify

NCT01745614

Bioequivalence Study of Nimesulide 100 mg Tablets

Completed Phase 1 Last updated 12 June 2017
What this trial tests

Phase 1 trial testing Nimesulide 100 mg tablets in Pain in 28 participants. Completed in 26 July 2010.

Timeline
18 July 2010
Primary endpoint
26 July 2010
26 July 2010

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment28
Start date18 July 2010
Primary completion26 July 2010
Estimated completion26 July 2010

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 40, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study was to confirm if two formulations of nimesulide tablets are bioequivalent. Test product was Eskaflam® (Nimesulide 100 mg tablets; GlaxoSmithKline) and reference product Mesulid® (Nimesulide 100 mg tablets; Syntex for Productos Roche). The single dosage was one tablet. The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions. The population was composed of 28 healthy volunteers, both genders, adults between 18-40 years. The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01745614.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing